Clinical Trials

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498635 2026-04-17

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06589804 2026-04-17

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT07061977 2026-04-17

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Not yet recruiting

336 enrolled

Gynecologic

Locally Advanced Cervical Adenocarcinoma

NCT07388524 2026-04-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05256225 2026-04-16

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT05642611 2026-04-16

ICE COMPRESS

777 enrolled

Other solid neoplasm

Malignant Solid Neoplasm

NCT06058377 2026-04-16

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06568172 2026-04-16

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

DermatologicHead & NeckSarcoma

420 enrolled

Eyelid Squamous Cell Carcinoma

NCT04269902 2026-04-15

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

LymphoidOther hematologic neoplasm

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06337318 2026-04-15

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

600 enrolled

Lymphoid

Classic Follicular Lymphoma

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT02912559 2026-04-14

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled 14 charts

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT06172296 2026-04-14

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

478 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06422806 2026-04-14

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

365 enrolled

Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT01886872 2026-04-13

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

547 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02595944 2026-04-13

ANVIL

903 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02997228 2026-04-13

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Colorectal Neoplasms

NCT03233711 2026-04-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03244384 2026-04-13

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03701282 2026-04-13

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03793166 2026-04-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

1,175 enrolled

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03811015 2026-04-13

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 2 FDA

Lymphoid

Hodgkin Disease

NCT04181060 2026-04-13

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

300 enrolled

Lung Neoplasms

NCT04214067 2026-04-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04214262 2026-04-13

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

480 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05092958 2026-04-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

654 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05675410 2026-04-13

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06732401 2026-04-13

CLEAR

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Not yet recruiting

255 enrolled

Gynecologic

Endometrial Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06745024 2026-04-08

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

280 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT03067181 2026-04-07

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

1,780 enrolled

Neoplasms, Germ Cell and Embryonal, Teratoma, Carcinoma, Embryonal, Endodermal Sinus Tumor

NCT03186898 2026-04-03

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

186 enrolled

Carcinoma, Hepatocellular

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT04804644 2026-04-03

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

200 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

1,209 enrolled

Prostatic Neoplasms

NCT06500481 2026-04-03

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Phase 3 Not yet recruiting

115 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT07441681 2026-04-03

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06915727 2026-04-01

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors